Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.25, FiscalAI reports. The company had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative net margin of 7,973.33% and a negative return on equity of 38.85%.
Dianthus Therapeutics Price Performance
DNTH stock traded up $0.90 during mid-day trading on Tuesday, hitting $90.24. The stock had a trading volume of 343,810 shares, compared to its average volume of 552,587. Dianthus Therapeutics has a 52 week low of $16.64 and a 52 week high of $96.50. The firm has a fifty day simple moving average of $79.60 and a 200 day simple moving average of $55.57.
Analyst Upgrades and Downgrades
A number of research firms recently commented on DNTH. HC Wainwright raised their price target on shares of Dianthus Therapeutics from $47.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, March 9th. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Oppenheimer raised their price target on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research report on Monday, March 9th. Wedbush raised their price target on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 10th. Finally, Truist Financial raised their target price on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $115.55.
Insider Activity at Dianthus Therapeutics
In other news, EVP Ryan Savitz sold 8,224 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $89.84, for a total value of $738,844.16. Following the sale, the executive vice president directly owned 8,224 shares in the company, valued at approximately $738,844.16. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Edward Carr sold 43,682 shares of the firm’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $3,559,646.18. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 323,021 shares of company stock valued at $26,564,008. 3.02% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Dianthus Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd acquired a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $40,000. Raymond James Financial Inc. acquired a new stake in Dianthus Therapeutics during the 2nd quarter worth approximately $27,000. Russell Investments Group Ltd. acquired a new stake in Dianthus Therapeutics during the 3rd quarter worth approximately $64,000. Royal Bank of Canada boosted its position in Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares during the period. Finally, Quarry LP acquired a new stake in Dianthus Therapeutics during the 4th quarter worth approximately $99,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.
Featured Articles
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
